In a study of 112 patients with CKD, increased levels of NGAL (>107.8 ng/mL) predicted a significantly higher decrease in eGFR in CKD stages 1 or 2 (p < 0.0001). This evidence concerns the gene LCN2 and chronic kidney disease.